Federal Register / Vol. 83, No. 123 / Tuesday, June 26, 2018 / Notices 29789 

A), LLC; International Transportation 

Service, Inc.; Pacific Maritime Services, 

L.L.C.; SSA Terminals, LLC; and Total 

Terminals International, LLC. 

Filing Party: Jeff Vogel; Cozen 

O’Connor. 

Synopsis: The amendment adds 

related provisions regarding the Port 

Drayage Truck Registry, extends the 

Agreement through July 1, 2021, and 

makes corrections to the names and 

addresses of some of the parties and 

administrative personnel. The parties 

request expedited review. 

Agreement No.: 011279–030. 

Title: Latin America Agreement. 

Parties: Central America Discussion 

Agreement; Caribbean Shipowners 

Association; ABC Discussion 

Agreement; West Coast of South 

America Discussion Agreement; and 

Zim Integrated Shipping Services, Ltd. 

Filing Party: Wayne Rohde; Cozen 

O’Connor. 

Synopsis: The amendment deletes the 

Venezuelan Discussion Agreement and 

Libra as parties and corrects the 

addresses of the remaining parties to the 

Agreement. 

Dated: June 21, 2018. 

JoAnne D. O’Bryant, 

Program Analyst. 

[FR Doc. 2018–13729 Filed 6–25–18; 8:45 am] 

BILLING CODE 6731–AA–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Agency Recordkeeping/Reporting 

Requirements Under Emergency 

Review by the Office of Management 

and Budget (OMB) 

Title: Information Collection for HHS 

Certification of Foreign Adult Victims of 

Human Trafficking. 

OMB No.: 0970–0454. 

Description: The Trafficking Victims 

Protection Act, Public Law 106–386 

(TVPA) requires the Department of 

Health and Human Services (HHS) to 

certify adult alien (‘‘foreign’’) victims of 

severe forms of trafficking in persons 

(‘‘human trafficking’’) who are willing to 

assist law enforcement in the 

investigation and prosecution of human 

trafficking, unless unable to cooperate 

due to physical or psychological trauma, 

and who have either made a bona fide 

application for T nonimmigrant status 

that has not been denied or been granted 

Continued Presence (CP) from the U.S. 

Department of Homeland Security 

(DHS). The Office on Trafficking in 

Persons (OTIP) within the HHS 

Administration for Children and 

Families issues HHS Certification 

Letters that grant adult foreign victims 

of human trafficking eligibility for 

federal and state benefits and services to 

the same extent as refugees. 

In general, OTIP initiates the 

certification process when it receives a 

notice from DHS that DHS has granted 

a foreign victim of trafficking CP or T 

nonimmigrant status, or has determined 

an application for T nonimmigrant 

status is bona fide. To issue HHS 

Certification Letters, it is necessary for 

OTIP to collect information from a 

victim, or a victim’s representative, such 

as an attorney, case manager, or law 

enforcement victim specialist, including 

an address to send the HHS Certification 

Letter. 

OTIP will ask if the victim is in need 

of case management services and the 

current location (city, state) of the 

victim, and refer the victim to an 

appropriate service provider in his or 

her area, if requested. OTIP will also ask 

about the victim’s primary language and 

urgent concerns, such as medical care or 

housing, and transmit this information 

to the service provider with the victim’s 

consent. 

Finally, OTIP reports information on 

victim certification to provide to 

Congress in an annual report on U.S. 

Government activities to combat 

trafficking that is prepared by the U.S. 

Department of Justice. Congress requires 

HHS and other appropriate Federal 

agencies to report information on the 

number of persons who received 

benefits or other services under 

subsections (b) and (f) of section 7105 of 

Title 22 of the U.S. Code in connection 

with programs or activities funded or 

administered by HHS. HHS may include 

in these annual reports additional 

aggregate information that it collects 

about the victims when assisting each 

victim to obtain HHS Certification. 

OTIP developed the form to facilitate 

the submission of consistent 

information and improve program 

reporting. The trafficking victim or his 

or her representative may submit the 

completed form, which we recommend 

be done via password-protected email or 

encryption, to OTIP for the purpose of 

issuing a Certification Letter. OTIP will 

store this information in OTIP’s secure 

database for no longer than 10 years, at 

which time it will be destroyed, unless 

required for business use by HHS. Other 

details maintained in the victim’s file 

may include OTIP staff actions, 

referrals, and notes regarding the 

victim’s interest in receiving services. 

Maintaining victim records within 

OTIP’s database will ensure efficient 

service delivery for victims, allow OTIP 

staff to track victims’ progress toward 

certification, verify eligibility for 

benefits, and organize information for 

reporting aggregate data to Congress. 

Respondents: Nongovernmental 

entities providing social or legal 

services, or victim/survivors of 

trafficking may use this form to submit 

a request for certification. The use of 

this form is optional; the victim or his/ 

her representative has the option to 

make a request for certification via 

telephone or email. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

hours per 

response 

Total burden 

hours 

HHS Certification Instrument ........................................................................... 800 1 .5 400 

Estimated Total Annual Burden 

Hours: 400. 

Additional Information: ACF is 

requesting that OMB grant a 180 day 

approval for this information collection 

under procedures for emergency 

processing by JUNE 22, 2018. A copy of 

this information collection, with 

applicable supporting documentation, 

may be obtained by calling the 

Administration for Children and 

Families, Reports Clearance Officer, 

Robert Sargis at (202) 690–7275. 

Comments and questions about the 

information collection described above 

should be directed to the Office of 

Information and Regulatory Affairs, 

Attn: OMB Desk Officer for ACF, Office 

of Management and Budget, Paperwork 

Reduction Project, 725 17th Street NW, 


sradovich on DSK3GMQ082PROD with NOTICES
29790 Federal Register / Vol. 83, No. 123 / Tuesday, June 26, 2018 / Notices 

Washington, DC 20503; FAX: (202) 395– 

7285; email: oira_submission@

omb.eop.gov. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2018–13604 Filed 6–25–18; 8:45 am] 

BILLING CODE 4184–47–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–1073] 

Antimicrobial Drugs Advisory 

Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; establishment of a 

public docket; request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) announces a 

forthcoming public advisory committee 

meeting of the Antimicrobial Drugs 

Advisory Committee. The general 

function of the committee is to provide 

advice and recommendations to FDA on 

regulatory issues. The meeting will be 

open to the public. FDA is establishing 

a docket for public comment on this 

document. 

DATES: The meeting will be held on July 

12, 2018, from 8:30 a.m. to 4 p.m. 

ADDRESSES: FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31 

Conference Center, the Great Room (Rm. 

1503), Silver Spring, MD 20993–0002. 

Answers to commonly asked questions 

including information regarding special 

accommodations due to a disability, 

visitor parking, and transportation may 

be accessed at: https://www.fda.gov/ 

AdvisoryCommittees/AboutAdvisory

Committees/ucm408555.htm. 

FDA is establishing a docket for 

public comment on this meeting. The 

docket number is FDA–2018–N–1073. 

The docket will close on July 11, 2018. 

Submit either electronic or written 

comments on this public meeting by 

July 11, 2018. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before July 11, 2018. 

The https://www.regulations.gov 

electronic filing system will accept 

comments until midnight Eastern Time 

at the end of July 11, 2018. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Comments received on or before July 

2, 2018, will be provided to the 

committee. Comments received after 

that date will be taken into 

consideration by FDA. 

You may submit comments as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2018–N–1073 for ‘‘Antimicrobial Drugs 

Advisory Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ FDA 

will review this copy, including the 

claimed confidential information, in its 

consideration of comments. The second 

copy, which will have the claimed 

confidential information redacted/ 

blacked out, will be available for public 

viewing and posted on https://

www.regulations.gov. Submit both 

copies to the Dockets Management Staff. 

If you do not wish your name and 

contact information be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify the information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov/ 

fdsys/pkg/FR-2015-09-18/pdf/2015- 

23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: 

Kalyani Bhatt, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, Fax: 301–847–8533, email: 

AMDAC@fda.hhs.gov, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

FDA’s website at https://www.fda.gov/ 


sradovich on DSK3GMQ082PROD with NOTICES